Literature DB >> 20819543

Association between painful physical symptoms and clinical outcomes in Chinese patients with major depressive disorder: a three-month observational study.

Hui-chun Li1, Ming-yuan Zhang, Gang Wang, Hong-geng Zhang, Hong-yan Zhang, Ying Liu, Ming Li, Cong-pei Zhang, Ji-sheng Tang, Wen-yuan Wu, Pritibha Singh, Renee Elizabeth Granger, Joel Raskin, Qiu-qing Ang.   

Abstract

BACKGROUND: Painful physical symptoms (PPS) may present as a component of major depressive disorder (MDD). Their effect in Chinese patients has not been investigated. This analysis reports the changes in disease severity, treatment patterns, quality of life and outcomes in a Chinese cohort according to the presence (PPS+) or absence (PPS-) of painful physical symptoms.
METHODS: A subgroup of Chinese patients from a large observational 3-month study of patients from Asian countries and regions of China were classified using the modified Somatic Symptom Inventory (SSI) as PPS+ (mean score >or= 2) or PPS- (mean score < 2). Depression severity was assessed with the Clinical Global Impression of Severity (CGI-S) scale and 17-item Hamilton depression rating scale (HAMD(17)). Pain severity was measured using a visual analogue scale (VAS), while the EuroQoL (EQ-5D) assessed patient well-being. Antidepressants were compared with regard to their efficacy.
RESULTS: Of the 299 Chinese patients enrolled in the study, 105 were classified as PPS+ (73/105, 70% women). At baseline, PPS+ patients reported greater pain severity (VAS, mean (SD): 49.56 (26.49) vs. 16.60 (20.99) for PPS-, P < 0.01), were more depressed (HAMD(17), mean (SD): 25.32 (5.47) vs. 23.33 (5.24) for PPS-, P = 0.002) and had poorer quality of life (EQ-5D Health State, mean (SD): 38.48 (22.38) vs. 49.57 (18.54) for PPS-, P < 0.001). PPS+ patients showed less overall improvement in depressive symptom severity (HAMD(17), change from baseline (95%CI): -17.38 (-18.65, -16.12) vs. -19.20 (-20.05, -18.35) for PPS-, P = 0.032; CGI-S, change from baseline (95%CI): -2.85 (-3.11, -2.58) vs. -3.20 (-3.38, -3.02) for PPS-, P = 0.044).
CONCLUSIONS: PPS were less frequent than expected compared with previous studies of Asian populations. PPS+ were associated with greater MDD severity and less improvement than PPS- when antidepressants were given.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819543

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  5 in total

1.  Semantic Examination of a Japanese Center for Epidemiologic Studies Depression: A Cautionary Analysis Using Mixed Methods.

Authors:  Denise Saint Arnault; Hiroyo Hatashita; Hitomi Suzuki
Journal:  Can J Nurs Res       Date:  2016 Sep-Dec

2.  Psychiatric morbidity in pain conditions: results from the Singapore Mental Health Study.

Authors:  Mythily Subramaniam; Janhavi Ajit Vaingankar; Edimansyah Abdin; Siow Ann Chong
Journal:  Pain Res Manag       Date:  2013 Jul-Aug       Impact factor: 3.037

3.  Association between pain severity, depression severity, and use of health care services in Japan: results of a nationwide survey.

Authors:  Jeffrey Vietri; Tempei Otsubo; William Montgomery; Toshinaga Tsuji; Eiji Harada
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-13       Impact factor: 2.570

4.  Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.

Authors:  James Brockbank; Taryn Krause; Emily Moss; Anne Milthers Pedersen; Michael Frank Mørup; Outi Ahdesmäki; Jake Vaughan; Thor-Henrik Brodtkorb
Journal:  Health Qual Life Outcomes       Date:  2021-03-18       Impact factor: 3.186

5.  Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trials.

Authors:  Eiji Harada; Hirofumi Tokuoka; Shinji Fujikoshi; Jumpei Funai; Madelaine M Wohlreich; Michael H Ossipov; Nakao Iwata
Journal:  Pain       Date:  2016-03       Impact factor: 7.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.